DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

ALX-009

Phase One

Phase One

Therapeutic Approach

Anti-Infective

ALX-009 is a combination of two substances found naturally in the body, hypothiocyanite (OSCN-) and lactoferrin. Both of these molecules are part of the body’s natural immune system, but they are deficient in the airway surface liquid of people with CF. By adding bothOSCN- and lactoferrin to the airways, ALX-009 may increase the ability of people with CF to fight bacteria without harming their body’s own cells. ALX-009 is delivered via inhalation.

Status

A Phase 1 study to test the safety and tolerability of ALX-009 is underway.

Sponsor

This program is sponsored by Alaxia and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT).

Contact us about ALX-009 >